NCT05181826 Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
| NCT ID | NCT05181826 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Helio Genomics |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2019-05-21 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,200 participants in total. It began in 2019-05-21 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Eligibility Criteria
Inclusion Criteria: 2.1.1 Age 18 years or older. 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. . Exclusion Criteria: 2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded. 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.
Contact & Investigator
Taggert
STUDY DIRECTOR
Helio Health
Frequently Asked Questions
Who can join the NCT05181826 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05181826 currently recruiting?
Yes, NCT05181826 is actively recruiting participants. Contact the research team at octavia@heliogenomics.com for enrollment information.
Where is the NCT05181826 trial being conducted?
This trial is being conducted at Redondo Beach, United States, Coon Rapids, United States, Fridley, United States, Minneapolis, United States and 3 additional locations.
Who is sponsoring the NCT05181826 clinical trial?
NCT05181826 is sponsored by Helio Genomics. The principal investigator is Taggert at Helio Health. The trial plans to enroll 1,200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.